 |
| Is this the way to Puerto Rico |
UNITED STATES OF AMERICA, STATES OF CALIFORNIA, DELAWARE, FLORIDA, GEORGIA, HAWAII , ILLINOIS, INDIANA, LOUISIANA, MASSACHUSETTS, MICHIGAN, NEVADA, NEW HAMPSHIRE, NEW MEXICO, NEW YORK, TENNESSEE, TEXAS, and VIRGINIA, THE DISTRICT OF COLUMBIA and THE CITIES OF CHICAGO AND NEW YORK, ex rel . CHERYL D. ECKARD,
Vs
SMITHKLINEBEECHAM CORPORATION D/B/A/ GLAXOSMITHKLINE, SB PHARMCO PUERTO RICO, INC. , and GLAXOSMITHKLINE PUERTO RICO, INC.
Browsing through the court documents has left me wondering how such malpractices were ignored for so long by GlaxoSmithKline.
It's common knowledge that Cheryl Eckard was appalled at the state of the plant in Puerto Rico, she even told her seniors, for this, it appears, she was fired.
The drugs affected by the Glaxo's conduct include Paxil, Paxil CR, Avandia, Avandamet, Coreg, Bactroban, Abreva, Cimetidine, Compazine, Denavir, Dyazide, Thorazine, Stelazine, Ecotrin, Tagamet, Relafen, Kytril, Factive, Dyrenium and Albenza.
Examples of defective and/or misidentified products that the defendants released to the United States market from the Cidra plant are:
a. Drug product that was mixed up with drug product of a different type or strength, e.g., 30mg and 10 mg tablets of an anti-depressant mixed in the same bottle, and 12.5 and 6.25 mg tablets of a heart medication mixed in the same bottle.
b. A diabetes medication that was sub-potent and/or superpotent.
c. An antibiotic ointment used to treat a skin infection common in small children that was contaminated with a microorganism associated with bacteranemia, urinary tract infections, meningitis, wound infection, and peritonitis.
d. An injectable drug used to treat nausea and vomiting in patients undergoing chemotherapy that was contaminated with micro-organisms.
Further, on information and belief, during the times relevant to this complaint employees of the defendants diverted reject drug product from the Cidra plant to black markets in Latin America. The defendants’ management failed adequately to investigate these allegations. On information and belief, this resulted in the distribution of reject drug product to the United States market and the submission of false claims for drug product that was defective.
You read it correct folks!
Antidepressants containing different dosage strengths.
Heart medication containing different strengths.
A diabetes medication with a defect.
A children's ointment that was contaminated with a microorganism associated with bacteranemia, urinary tract infections, meningitis, wound infection, and peritonitis.
And a injectable drug used to treat nausea and vomiting in patients undergoing chemotherapy that was contaminated with micro-organisms.
Not content with the piss poor management of regulating the manufacturing of medications it was also alleged that employees of GlaxoSmithKline diverted reject drug product from the Cidra plant to black markets in Latin America.
"Hey senor, you wanna buy some sheeeeeeet."
Glaxo pleaded guilty to charges brought against them and were fined $750 million.
It is claimed that none of the defective products left the Puerto Rican plant.
GlaxoSmithKline
Do more, feel better, live longer
DOWNLOAD THE PDF
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
No comments: